3,3-二甲基吡咯烷 | 3437-30-7

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 吡咯烷类
• 中文名称: 3,3-二甲基吡咯烷
• 中文别名: 3,3-二甲基吡咯盐酸盐
• 英文名称: 3,3-dimethylpyrrolidine
• CAS: 3437-30-7
• 化学式: C₆H₁₃N
• mdl: MFCD09864370
• 分子量: 99.1759
• InChiKey: XBQNZPDIRJPFAI-UHFFFAOYSA-N

物化性质

• 沸点：
  81 °C(Press: 13 Torr)
• 密度：
  0.8422 g/cm3
• 保留指数：
  778;778

计算性质

• 辛醇/水分配系数(LogP)：
  1.1
• 重原子数：
  7
• 可旋转键数：
  0
• 环数：
  1.0
• sp3杂化的碳原子比例：
  1.0
• 拓扑面积：
  12
• 氢给体数：
  1
• 氢受体数：
  1

安全信息

• 危险品标志：
  Xi
• 海关编码：
  2933990090

反应信息

• 作为反应物：
  描述：

  3,3-二甲基吡咯烷 在 仲丁基锂 、 鹰爪豆碱 作用下， 以 四氢呋喃 、 甲基叔丁基醚 为溶剂， 反应 24.5h， 生成 tert-butyl (R)-4,4-dimethyl-2-(pyridin-3-yl)pyrrolidine-1-carboxylate
  参考文献：
  名称：

  Novel 3-O-carbamoyl erythromycin A derivatives (carbamolides) with activity against resistant staphylococcal and streptococcal isolates

  摘要：

  A novel series of 3-O-carbamoyl erythromycin A derived analogs, labeled carbamolides, with activity versus resistant bacterial isolates of staphylococci (including macrolide and oxazolidinone resistant strains) and streptococci are reported. An (R)-2-aryl substituent on a pyrrolidine carbamate appeared to be critical for achieving potency against resistant strains. Crystal structures showed a distinct aromatic interaction between the (R)-2-aryl (3-pyridyl for 4d) substituent on the pyrrolidine and G2484 (G2505, Escherichia coli) of the Deinococcus radiodurans 50S ribosome (3.2 angstrom resolution). (C) 2013 Elsevier Ltd. All rights reserved.

  DOI：

  10.1016/j.bmcl.2013.01.067
• 作为产物：
  描述：

  2,2-二甲基琥珀酸 在 lithium aluminium tetrahydride 、 尿素 作用下， 以 四氢呋喃 为溶剂， 反应 27.0h， 生成 3,3-二甲基吡咯烷
  参考文献：
  名称：

  Novel 3-O-carbamoyl erythromycin A derivatives (carbamolides) with activity against resistant staphylococcal and streptococcal isolates

  摘要：

  A novel series of 3-O-carbamoyl erythromycin A derived analogs, labeled carbamolides, with activity versus resistant bacterial isolates of staphylococci (including macrolide and oxazolidinone resistant strains) and streptococci are reported. An (R)-2-aryl substituent on a pyrrolidine carbamate appeared to be critical for achieving potency against resistant strains. Crystal structures showed a distinct aromatic interaction between the (R)-2-aryl (3-pyridyl for 4d) substituent on the pyrrolidine and G2484 (G2505, Escherichia coli) of the Deinococcus radiodurans 50S ribosome (3.2 angstrom resolution). (C) 2013 Elsevier Ltd. All rights reserved.

  DOI：

  10.1016/j.bmcl.2013.01.067

文献信息

• Design, Synthesis, and Pharmacological Characterization of a Neutral, Non-Prodrug Thrombin Inhibitor with Good Oral Pharmacokinetics
  作者：Alexander Hillisch、Kersten M. Gericke、Swen Allerheiligen、Susanne Roehrig、Martina Schaefer、Adrian Tersteegen、Simone Schulz、Philip Lienau、Mark Gnoth、Vera Puetter、Roman C. Hillig、Stefan Heitmeier

  DOI：10.1021/acs.jmedchem.0c01035

  日期：2020.11.12

  Despite extensive research on small molecule thrombin inhibitors for oral application in the past decades, only a single double prodrug with very modest oral bioavailability has reached human therapy as a marketed drug. We have undertaken major efforts to identify neutral, non-prodrug inhibitors. Using a holistic analysis of all available internal data, we were able to build computational models and

  尽管在过去的几十年中对口服的小分子凝血酶抑制剂进行了广泛的研究，但只有一种具有非常适度的口服生物利用度的双前药已作为上市药物进入了人类治疗。我们已做出重大努力，以鉴定中性，非前药抑制剂。通过对所有可用内部数据的整体分析，我们能够建立计算模型，并将其用于选择具有最高口服生物利用度可能性的先导系列。在我们的设计中，我们依靠蛋白质结构知识来解决效价问题，并确定了有利理化特性的小窗口以平衡吸收和代谢稳定性。孕烷X受体的蛋白质结构信息有助于克服持续存在的细胞色素P450 3A4诱导问题。通过设计，合成和测试衍生物，将所选化合物系列优化为高效，中性，非前药凝血酶抑制剂。所得的优化化合物BAY1217224已达到首次临床试验，已经证实了所需的药代动力学特性。
• [EN] HETEROARYL DERIVATIVES AS SEPIAPTERIN REDUCTASE INHIBITORS<br/>[FR] DÉRIVÉS D'HÉTÉROARYLE À UTILISER EN TANT QU'INHIBITEURS DE SÉPIAPTÉRINE RÉDUCTASE
  申请人：QUARTET MEDICINE INC

  公开号：WO2017059191A1

  公开（公告）日：2017-04-06

  Inhibitors of sepiapterin reductase of formula (I) or (I'), wherein the substituents are defined as in the claims, and uses of sepiapterin reductase inhibitors in analgesia, treatment of acute and chronic pain, anti-inflammation, and immune cell regulation are disclosed.

  式(I)或(I')的色氨酰还原酶抑制剂，其中取代基如权利要求中所定义，以及这些色氨酰还原酶抑制剂在镇痛、治疗急慢性疼痛、抗炎和免疫细胞调节中的用途被公开。
• [EN] PIPERIDINYLPYRAZOLOPYRIMIDINONES AND THEIR USE<br/>[FR] PIPÉRIDINYLPYRAZOLOPYRIMIDINONES ET LEUR UTILISATION
  申请人：BAYER PHARMA AG

  公开号：WO2016071216A1

  公开（公告）日：2016-05-12

  The present application relates to novel substituted piperidinylpyrazolopyrimidinones, to processes for their preparation, the compounds for use alone or in combinations in a method for the treatment and/or prophylaxis of diseases, in particular for the treatment and/or prophylaxis of acute and recurrent bleeding in patients with or without underlying hereditary or acquired hemostatic disorders, wherein the bleeding is associated with a disease or medical intervention selected from the group consisting of heavy menstrual bleeding, postpartum hemorrhage, hemorrhagic shock, hemorrhagic cystitis, gastrointestinal hemorrhage, trauma, surgery, transplantation, stroke, liver diseases, hereditary angioedema, nosebleed, and synovitis and cartilage damage following hemarthrosis.

  本申请涉及新型取代哌啶基吡唑吡嘧啶酮，以及它们的制备方法，这些化合物可单独或组合使用于治疗和/或预防疾病的方法中，特别是用于治疗和/或预防患有或不患有基础遗传或获得性止血障碍的患者的急性和复发性出血，其中出血与从重经期出血、产后出血、出血性休克、出血性膀胱炎、胃肠道出血、创伤、手术、移植、中风、肝脏疾病、遗传性血管性水肿、鼻血、以及血液积聚后的滑膜炎和软骨损伤等一组疾病或医疗干预有关。
• [EN] SUBSTITUTED 6-AZABENZIMIDAZOLE COMPOUNDS HAVING HPK1 INHIBITORY ACTIVITY<br/>[FR] COMPOSÉS 6-AZABENZIMIDAZOLE SUBSTITUÉS AYANT UNE ACTIVITÉ INHIBITRICE DE HPK1
  申请人：GILEAD SCIENCES INC

  公开号：WO2020092528A1

  公开（公告）日：2020-05-07

  The present disclosure relates generally to certain 6-azabenzimidazole compounds, pharmaceutical compositions comprising said compounds, and methods of making and using said compounds and pharmaceutical compositions. The compounds and compositions disclosed herein may be used for the treatment or prevention of diseases, disorders, or infections modifiable by hematopoietic progenitor kinase 1 (HPK1) inhibitors, such as HBV, HIV, cancer, and/or a hyper-proliferative disease.

  本公开涉及某些6-氮杂苯并咪唑化合物，包括该化合物的药物组合物，以及制备和使用该化合物和药物组合物的方法。本文披露的化合物和组合物可用于治疗或预防可通过造血祖细胞激酶1（HPK1）抑制剂改变的疾病、紊乱或感染，如乙型肝炎病毒（HBV）、人类免疫缺陷病毒（HIV）、癌症和/或过度增殖性疾病。
• [EN] GLUCOSYLCERAMIDE SYNTHASE INHIBITORS FOR THE TREATMENT OF DISEASES<br/>[FR] INHIBITEURS DE LA GLUCOSYLCÉRAMIDE SYNTHASE POUR LE TRAITEMENT DE MALADIES
  申请人：BIOMARIN PHARM INC

  公开号：WO2015042397A1

  公开（公告）日：2015-03-26

  Described herein are compounds of Formula I, methods of making such compounds, pharmaceutical compositions and medicaments containing such compounds, and methods of using such compounds to treat or prevent diseases or conditions associated with the enzyme glucosylceramide synthase (GCS).

  本文描述了一种I式化合物，制备这种化合物的方法，含有这种化合物的药物组合物和药物，以及使用这种化合物治疗或预防与葡萄糖酰胺合成酶（GCS）相关的疾病或症状的方法。